Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Triptorelin

Decapeptyl, Trelstar, Gonapeptyl, Pamorelin

Quick Stats
Studies 178
Trials 100
Unknown NA INTERVENTIONAL NCT05838105

Two Different Types of Luteal Phase Support in Natural Cycle Frozen Embryo Transfer and Its Effect on Pregnancy Rates

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The aim of the study is to compare the pregnancy rate between women treated with Gonadotropin Releasing Hormone (GnRH) agonist together with Human Chorionic Gonadotropin (HCG) and standard luteal support with progesterone following transfer of frozen embryos in in-vitro-fertilization (IVF) natural cycles.

Detailed Description

The rate of frozen embryos transfer (FET) has increased in recent years due to a higher tendency of single embryo transfer, use of preimplantation genetic testing, and prevention of ovarian hyperstimulation. There are different methods to prepare the endometrium for FET: 1. Natural cycle (NC) - natural preparation of the body for implantation without the need for medicinal intervention. 2. Modified natural cycle (mNC) - Inducing ovulation by administration of Human Chorionic Gonadotropin (HCG) trigger. 3. Medical - preparation of endometrium with hormones (estrogen and progesterone). Following embryo transfer, luteal phase support should be considered. Administration of treatment depends on the type of cycle chosen (either natural or medicated). Treatment options include progesterone, HCG and Gonadotropin Releasing Hormone (GnRH) analog - either one of them or combined. Different protocols (dosages and duration of use) with different pregnancy outcomes were explore before with inconclusive results. We wish to investigate administration of GnRH agonist+HCG vs. progesterone. Patients included in the study will be women undergoing natural cycle FET at the IVF center in Shaare Zedek, Jerusalem, Israel. All patients will be randomly divided into two groups, each will receive a different luteal treatment support as will be detailed later. Patients demographic data and pregnancy outcomes will be collected. Based on the clinical pregnancy rate in the prospective study by Bjuresten, et al \[Fertil Steril, 2011\], where a clinical pregnancy rate of 32% was found among women treated with progesterone for luteal support, and given an alpha of 5% and a power of 80%, 144 women (72 women in each group) are required in order to demonstrate a clinical pregnancy rate of 55% in the study group. Comparison of categorical variables will be carried out using the the chi-squared test. Comparison of continuous variables will be performed using the Students t-Test or Mann-Whitney U method depending on the variable distribution (normal vs. non-normal distribution, respectively). A multivariate regression will also be conducted in order to determine which variables are significantly and independently related. Statistical significance will be defined when P values are less than 0.05

Interventions

Name: GnRH agonist
Type: DRUG
Description: 125 mcg once at the day mentioned
Name: hCG
Type: DRUG
Description: dose as mentioned
Name: Progesterone 100Mg Vag Tab
Type: DRUG
Description: dose as mentioned

Primary Outcomes

Measure: Clinical pregnancy rate
TimeFrame: up to two month after embryo transfer
Description: visualization of intrauterine gestational sac on ultrasound divided by number of transfers

Trial Information

NCT ID

NCT05838105

Status

Unknown

Study Type

INTERVENTIONAL

Phases

NA

Sponsor

Shaare Zedek Medical Center

Last Updated

December 15, 2025